Previous 10 | Next 10 |
P latform and P oster Presentation s on Vyant Bio’s Human First Drug Discovery Platform and Progress on CDKL5 Deficiency Disorder (CDD) CHERRY HILL, N.J., Oct. 27, 2022 (GLOBE NEWSWI...
- To Discuss its Novel Drug Discovery Platform that i s A ccelerat ing the P rocess of F inding C ures for N eurogenerative D iseases ...
- I nvites individual and institutional investors, as well as advisors and analysts, to attend this real-time, interactive presentation at the Skyline Signature Series ™ CHERRY HILL, N.J., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (...
CHERRY HILL, N.J., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’...
Vyant Bio, Inc. (VYNT) Q2 2022 Results Earnings Conference Call August 22, 2022, 04:30 PM ET Company Participants Jay Roberts - President and Chief Executive Officer Andrew LaFrence - Chief Financial Officer Robert Fremeau - Chief Scientific Officer Confere...
Vyant Bio press release ( NASDAQ: VYNT ): Q2 GAAP EPS of -$0.20. Revenue of $0.17M (-48.5% Y/Y). Cash and cash equivalents totaled $11.7M as of June 30, 2022. For further details see: Vyant Bio GAAP EPS of -$0.20, revenue of $0.17M
Conference Call and Webcast Today at 4:30 pm ET Scientific and Business Highlights Based on preclinical efficacy data in our human Rett cortical organoid model, we are advancing VYNT0126 into clinical trials in Rett patients with encouragement...
CHERRY HILL, N.J., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’...
Vyant Bio (NASDAQ: VYNT) is an innovative biotechnology company is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The company’s central nervous system (“CNS”) drug discovery platform combin...
CHERRY HILL, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’...
News, Short Squeeze, Breakout and More Instantly...
Signature Bank (SBNY) is expected to report for Q3 2023 BHP Group Ltd. (BHP) is expected to report for Q1 2024 Sorrento Therapeutics Inc. (SRNEQ) is expected to report $-0.15 for Q3 2023 Baran Group Ltd. (BRANF) is expected to report for quarter end 2023-09-30 World Copper (WCUFF)...
GLG Life Tech Corporation (GLGLF) is expected to report for Q1 2024 Accenture plc Class A (Ireland) (ACN) is expected to report $3.14 for Q1 2024 Greenlane Holdings Inc. (GNLN) is expected to report $-2.7 for Q3 2023 iMedia Brands Inc. (IMBIQ) is expected to report for quarter end 202...
Axcella Health Inc. (AXLA) is expected to report for Q3 2023 Telekom Malaysia Bhd (MYTEF) is expected to report for quarter end 2023-09-30 Atento S.A. (ATTOF) is expected to report for Q3 2023 Scryb Inc Com (SCYRF) is expected to report for Q4 2023 BHP Group Ltd. (BHP) is expected...